{
    "id": 27840,
    "fullName": "FGFR2 - DNM3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-DNM3 results from the fusion of FGFR2 and DNM3, resulting in FGFR2 activation, increased PI3K and MAPK pathway signaling, and increased colony formation in culture (PMID: 29203461). FGFR2-DNM3 has been identified in triple-receptor negative breast cancer (PMID: 29203461).",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - DNM3",
    "createDate": "04/23/2018",
    "updateDate": "04/23/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 26052,
                "geneSymbol": "DNM3",
                "terms": [
                    "DNM3",
                    "Dyna III"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13765,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with BKM120 demonstrated only delayed tumor progression when compared to treatment with BGJ398, which resulted in tumor regression (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 were sensitive to treatment with BGJ398, demonstrating tumor regression, however, after 43 days on average, three out of six models developed resistance (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13766,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 treated with a combination of BGJ398 and Lynparza (olaparib) demonstrated a complete response and did not develop resistance as compared to those models treated with BGJ398 alone (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 6894,
                "therapyName": "BGJ398 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with a combination of BGJ398 and Talazoparib (BMN-673) demonstrated a complete response and no relapse within 80 days (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 6895,
                "therapyName": "BGJ398 + Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29402,
            "profileName": "FGFR2 - DNM3",
            "profileTreatmentApproaches": [
                {
                    "id": 19609,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 - DNM3"
                },
                {
                    "id": 19608,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 - DNM3"
                }
            ]
        },
        {
            "id": 29408,
            "profileName": "FGFR2 - DNM3 BRCA1 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}